WOOJUNG BIO Inc
WOOJUNG BIO, Inc. provides non-clinical research agency services. The company was founded in 1989 and is based in Hwaseong-si, South Korea.
WOOJUNG BIO Inc (215380) - Total Liabilities
Latest total liabilities as of September 2025: ₩65.22 Billion KRW
Based on the latest financial reports, WOOJUNG BIO Inc (215380) has total liabilities worth ₩65.22 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
WOOJUNG BIO Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how WOOJUNG BIO Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
WOOJUNG BIO Inc Competitors by Total Liabilities
The table below lists competitors of WOOJUNG BIO Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Trigg Minerals Limited
OTCQB:TMGLF
|
USA | $760.56K |
|
Birla Cable Limited
NSE:BIRLACABLE
|
India | ₹1.62 Billion |
|
Hipay Group SA
PA:ALHYP
|
France | €173.68 Million |
|
Haesung Optics Co. Ltd
KQ:076610
|
Korea | ₩108.03 Billion |
|
Eutilex.Co.Ltd
KQ:263050
|
Korea | ₩22.09 Billion |
|
Enimmune corporation
TWO:6564
|
Taiwan | NT$296.91 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down WOOJUNG BIO Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how WOOJUNG BIO Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for WOOJUNG BIO Inc (2016–2024)
The table below shows the annual total liabilities of WOOJUNG BIO Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩65.33 Billion | -14.45% |
| 2023-12-31 | ₩76.36 Billion | +16.98% |
| 2022-12-31 | ₩65.28 Billion | -4.95% |
| 2021-12-31 | ₩68.68 Billion | +64.36% |
| 2020-12-31 | ₩41.78 Billion | +34.91% |
| 2019-12-31 | ₩30.97 Billion | +31.15% |
| 2018-12-31 | ₩23.61 Billion | +80.62% |
| 2017-12-31 | ₩13.07 Billion | +812.36% |
| 2016-12-31 | ₩1.43 Billion | -- |